{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-026392","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.004438+00:00","generated_at":"2026-05-24T08:25:25.832644+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Traws Pharma tivoxavir marboxil shows 100% survival in H5N1 rodent model; Phase 1 PK positive","bullets":["100% of TXM-treated mice survived lethal H5N1 challenge; all untreated controls died by study day 6.","Single 240 mg dose maintained plasma levels at EC90 for ~25 days; well tolerated up to 480 mg in Phase 1.","TXM exhibited sub-nanomolar EC50 against circulating 2022-2023 H5N1 strains and baloxavir-resistant viruses.","Investor call scheduled for March 31, 2025 at 10:00 AM ET to review antiviral programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-026392","json":"https://secwatch.observer/filing/0001104659-25-026392.json","markdown":"https://secwatch.observer/filing/0001104659-25-026392.md","text":"https://secwatch.observer/filing/0001104659-25-026392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925026392/0001104659-25-026392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925026392/tm259925d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T08:25:25.832644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}